Potential predictors for neoadjuvant chemoradiation in locally advanced rectal cancer

doi:10.3877/cma.j.issn.2095-3224.2016.05.013

Abstract

Abstract:

Neoadjuvant chemoradiation followed by surgical treatment has become the standard treatment for LARC. Accurate prediction of rectal tumor regression after neoadjuvant chemotherapy, especially pathological complete remission, has been very important, which helps to develop individualized treatment plan for patients. Thus, potential predictors of locally advanced rectal cancer patients treated with neoadjuvant chemoradiation are reviewed and analyzed here, and prospect of development of these predictor were discussed.

Key words: Colorectal neoplasms, Therapy, Neoadjuvant chemoradiotherapy, Therapeutic predictor

Bo Luo, Hao Lei. Potential predictors for neoadjuvant chemoradiation in locally advanced rectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(05): 434-439.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.05.013

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I05/434

References 41

[1]	Du CZ,Li J,Cai Y,et al. Effect of multidisciplinary teamtreatment on outcomes of patients with gastro intestinal malignancy[J]. World J Gastroenterol, 2010, 17(15): 2013-2018.
[2]	Chen MB,Wu XY,Yu R, et al. P53 status as a predictive biomarker for patientsreceiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer[J]. PLoS One, 2012, 7(9): e45388.
[3]	Duldulao MP,Lee W,Nelson RA, et al. Mutations in specific codons of theKRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma[J]. Ann Surg Oncol, 2013, 20(7): 2166-2171.
[4]	Bengala C,Bettelli S,Bertolini F, et al. Prognostic role of EGFR gene copynumber and KRAS mutation in patients with locally advanced rectal cancertreated with preoperative chemoradiotherapy[J]. Br J Cancer, 2010, 103(7): 1019-1024.
[5]	Gaedcke J,Grade M,Jung K, et al. KRAS and BRAF mutations in patients withrectal cancer treated with preoperative chemoradiotherapy[J]. Radiother Oncol, 2010, 94(1): 76-81.
[6]	Luna-Perez P,Segura J,Alvarado I, et al. Specific c-K-ras gene mutations as atumor-response marker in locally advanced rectal cancer treated with preoperativechemoradiotherapy[J]. Ann Surg Oncol, 2000, 7(10): 727-731.
[7]	Hur H,Kang J,Kim NK, et al. Thymidylate synthase gene polymorphism affectsthe response to preoperative 5-fluorouracil chemoradiation therapy in patientswith rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(3): 669-676.
[8]	Cecchin E,Agostini M,Pucciarelli S, et al. Tumor response is predicted bypatient genetic profile in rectal cancer patients treated with neo-adjuvant chemoradiotherapy[J]. Pharmacogenomics J, 2011, 11(3): 214-226.
[9]	Grade M,Gaedcke J,Wangsa D, et al. Chromosomal copy number changes oflocally advanced rectal cancers treated with preoperative chemoradiotherapy[J]. Cancer Genet Cytogenet, 2009, 193(1): 19-28.
[10]	Chen Z,Liu Z,Li W, et al. Chromosomal copy number alterations are associatedwith tumor response to chemoradiation in locally advanced rectal cancer[J]. GenesChromosomes Cancer, 2011, 50(9): 689-699.
[11]	Zaki BI,Suriawinata AA,Eastman AR, et al. Chromosomal instability portendssuperior response of rectal adenocarcinoma to chemoradiation therapy[J]. Cancer, 2014, 120(11): 1733-1742.
[12]	Ghadimi BM,Grade M,Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy[J]. J Clin Oncol, 2005, 23(9): 1826-1838.
[13]	Palma P,Cano C,Conde-Muino R, et al. Expression profiling of rectal tumors defines response to neoadjuvant treatment related genes[J]. PLoS One, 2014, 9(11): e112189.
[14]	Gantt GA,Chen Y,Dejulius K, et al. Gene expression profile is associated withchemoradiation resistance in rectal cancer[J]. Colorectal Dis, 2014, 16(1): 57-66.
[15]	Akiyoshi T,Kobunai T,Watanabe T. Predicting the response to preoperativeradiation or chemoradiation by a microarray analysis of the gene expressionprofiles in rectal cancer[J]. Surg Today, 2012, 42(8): 713-719.
[16]	Watanabe T,Kobunai T,Akiyoshi T, et al. Prediction of response to preoperativechemoradiotherapy in rectal cancer by using reverse transcriptase polymerasechain reaction analysis of four genes[J]. Dis Colon Rectum, 2014, 57(1): 23-31.
[17]	Zielske SP. Epigenetic DNA methylation in radiation biology: on the field or onthe sidelines[J]? J Cell Biochem, 2015, 116(2): 212-217.
[18]	Jo P,Jung K,Grade M, et al. CpG island methylator phenotype infers apoor disease-free survival in locally advanced rectal cancer[J]. Surgery, 2012, 151(4): 564-570.
[19]	Molinari C,Casadio V,Foca F, et al. Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy[J]? J Cell Physiol, 2013, 228(12): 2343-2349.
[20]	Drebber U,Lay M,Wedemeyer I, et al. Altered levels of the onco-microRNA21 and the tumor-supressor microRNAs 143 and 145 in advanced rectalcancer indicate successful neoadjuvant chemoradiotherapy[J]. Int J Oncol, 2011, 39(2): 409-415.
[21]	Della Vittoria Scarpati G,Falcetta F,Carlomagno C, et al. A specific miRNAsignature correlates with complete pathological response to neoadjuvant chemoradiotherapyin locally advanced rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 83(4): 1113-1119.
[22]	Svoboda M,Izakovicova Holla L,Sefr R, et al. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapyof rectal cancer[J]. Int J Oncol, 2008, 33(3): 541-547.
[23]	Svoboda M,Sana J,Fabian P, et al. MicroRNA expression profile associated withresponse to neoadjuvant chemoradiotherapy in locally advanced rectal cancerpatients[J]. Radiat Oncol, 2012, 7(1):195.
[24]	Bandres E,Arias F,Guerrero D, et al. Association between a specific miRNAsignature and pathological response to neoadjuvant chemoradiotherapy (CRT) inlocally advanced rectal cancer (LARC) patients (abstract e14057)[J]. J Clin Oncol, 2012, 30(15 suppl): e14057.
[25]	Meng X,Huang Z,Wang R, et al. Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer[J]. Biosci Trends, 2014, 8(1): 11-23.
[26]	Hur H,Kim NK,Min BS, et al. Can a biomarker-based scoring system predictpathologic complete response after preoperative chemoradiotherapy for rectalcancer[J]? Dis Colon Rectum, 2014, 57(5): 592-601.
[27]	Drebber U,Madeja M,Odenthal M, et al. Beta-catenin and HER2/neu expression in rectal cancer: association with histomorphological response toneoadjuvant therapy and prognosis[J]. Int J Colorectal Dis, 2011, 26(9): 1127-1134.
[28]	Bhangu A,Wood G,Brown G, et al. The role of epithelial mesenchymal transitionand resistance to neoadjuvant therapy in locally advanced rectal cancer[J]. Colorectal Dis, 2014, 16(4): 0133-0143.
[29]	Wang L,Zhang XM,Li Z, et al. Overexpression of nuclear beta-catenin in rectaladenocarcinoma is associated with radioresistance[J]. World J Gastroenterol, 2013, 19(40): 6876-6882.
[30]	Gillet JP,Efferth T,Remacle J. Chemotherapy-induced resistance by ATPbindingcassette transporter genes[J]. Biochim Biophys Acta, 2007, 1775(2): 237-262.
[31]	Yu ZQ,Zhang C,Wang H, et al. Downregulation of ATP-binding cassette subfamily C member 4 increases sensitivity to neoadjuvant radiotherapy forlocally advanced rectal carcinoma[J]. Dis Colon Rectum, 2013, 56(5): 600-608.
[32]	Yu Z,Zhang C,Chai R, et al. Prognostic significance and molecular mechanismof ATP-binding cassette subfamily C member 4 in resistance to neoadjuvantradiotherapy of locally advanced rectal carcinoma[J]. PLoS One, 2014, 9(1): e85446.
[33]	Yu Z,Zhang C,Wang H, et al. Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactiveoxygen species and caspase-3-dependent apoptotic pathway[J]. Cancer Lett, 2014, 353(2): 182-193.
[34]	Das P,Skibber JM,Rodriguez-Bigas MA, et al. Predictors of tumor response anddownstaging in patients who receive preoperative chemoradiation for rectalcancer[J]. Cancer, 2007, 109(9): 1750-1755.
[35]	Yang KL,Yang SH,Liang WY, et al. Carcinoembryonic antigen (CEA) level,CEA ratio, and treatment outcome of rectal cancer patients receiving preoperativechemoradiation and surgery[J]. Radiat Oncol, 2013, 8: 43.
[36]	Zitt M,Muller HM,Rochel M, et al. Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation:a potential diagnostic tool for therapy monitoring[J]. Dis Markers, 2008, 25(3): 159-165.
[37]	Agostini M,Pucciarelli S,Enzo MV, et al. Circulating cell-free DNA: a promisingmarker of pathologic tumor response in rectal cancer patients receiving preoperativechemoradiotherapy[J]. Ann Surg Oncol, 2011, 18(9): 2461-2468.
[38]	Terrin L,Rampazzo E,Pucciarelli S, et al. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implicationsfor monitoring of neoplastic disease[J]. Clin Cancer Res, 2008, 14(22): 7444-7451.
[39]	Pucciarelli S,Rampazzo E,Briarava M, et al. Telomere-specific reverse transcriptase(hTERT) and cell-free RNA in plasma as predictors of pathologic tumorresponse in rectal cancer patients receiving neoadjuvant chemoradiotherapy[J]. AnnSurg Oncol, 2012, 19(9): 3089-3096.
[40]	Smith FM,Gallagher WM,Fox E, et al. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumorsundergoing multimodal neoadjuvant therapy[J]. Ann Surg, 2007, 245(2): 259-266.
[41]	Palma P,Cuadros M,Conde-Muino R, et al. Microarray profiling of mononuclearperipheral blood cells identifies novel candidate genes related to chemoradiationresponse in rectal cancer[J]. PLoS One, 2013, 8(9): e74034.

Please choose a citation manager

Content to export